Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475308 | 0.78 | MAP4K4 (0.46) | SCN9ASCN10AMAP4K4FFAR1CNR1 | |
| SCHEMBL3475806 | 0.70 | SCN9A (0.37) | SCN9ASCN10AMAP4K4FFAR1CNR1 | |
| SCHEMBL3475804 | 0.67 | SCN9A (0.36) | SCN9ASCN10AMAP4K4CNR1NR3C1 | |
| SCHEMBL31292214 | 0.66 | DGAT1 (0.39) | SCN9A | |
| SCHEMBL27913818 | 0.66 | KDM4E (0.39) | SCN9ASCN10AFFAR1 | |
| SCHEMBL12093558 | 0.63 | NNMT (0.44) | — | |
| SCHEMBL17608798 | 0.62 | P2RX7 (0.37) | SCN9ASCN10A | |
| SCHEMBL31560751 | 0.62 | P2RX7 (0.37) | SCN9ASCN10A | |
| SCHEMBL31292391 | 0.61 | CYP2C19 (0.46) | SCN9ACNR2 | |
| SCHEMBL31292312 | 0.61 | DAO (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1641493-A4 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
| EP-1641493-A1 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005009479-A1 | RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115425-A1 | Substituted amides | CNR1, CNR2, FAAH | SCN9A 1970/4885SCN10A 1591/4885MAP4K4 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.